Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q2 FY24 results · Jul–Sep 2023
Alkem Laboratories reported revenue from operations of ₹3,440.17 crore (up 11.7% from Q2 FY23) and net profit of ₹614.89 crore (up 76.8% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,440.17 | 3,079.37 | +11.7% | 2,967.72 | +15.9% |
| Other income | 63.19 | 50.67 | +24.7% | 65.84 | −4.0% |
| Total income | 3,503.36 | 3,130.04 | +11.9% | 3,033.56 | +15.5% |
| Profit before tax | 648.04 | 402.33 | +61.1% | 352.85 | +83.7% |
| Net profit for the period | 614.89 | 347.72 | +76.8% | 287.81 | +113.6% |
| Attributable to shareholders of the company | 620.52 | 330.84 | +87.6% | 286.73 | +116.4% |
| EPS, basic (₹) | 51.90 | 27.67 | +87.6% | 23.98 | +116.4% |
| Net margin (%) | 17.9 | 11.3 | 9.7 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,634.59 | 2,461.49 | +7.0% | 2,253.17 | +16.9% |
| Other income | 61.84 | 73.64 | −16.0% | 64.70 | −4.4% |
| Total income | 2,696.43 | 2,535.13 | +6.4% | 2,317.87 | +16.3% |
| Profit before tax | 638.72 | 401.56 | +59.1% | 318.92 | +100.3% |
| Net profit for the period | 646.51 | 350.69 | +84.4% | 271.44 | +138.2% |
| EPS, basic (₹) | 54.07 | 29.33 | +84.4% | 22.70 | +138.2% |
| Net margin (%) | 24.5 | 14.2 | 12.0 |
Consolidated
- Filed with BSE
- 08 Nov 2023, 15:49 IST
- Board meeting
- 07 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Nov 2023, 15:49 IST
- Board meeting
- 07 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE